USPTO serial 79217305
Reviewed by CopyMark Law Group
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
CH-4123 Allschwil, CH
CH-4123 Allschwil, CH
CH-4123 Allschwil, CH
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Scott D. Woldow
SCOTT D. WOLDOW SMITH, GAMBRELL, RUSSELL, LLP1055 THOMAS JEFFERSON ST NW STE 400WASHINGTON, DC 20007UNITED STATES| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry, [ science, photography, ] * Chemical preparations for scientific purposes (other than for medical or veterinary use), Chemical preparations for use in photography, * as well as in agriculture, horticulture and forestry * except fungicides, weedkillers, herbicides, insecticides and parasiticides * ; unprocessed artificial resins, unprocessed plastics; soil fertilizers; fire-extinguishing compositions; tempering preparations and soldering chemicals; chemical substances for preserving foodstuffs; tanning agents for use in manufacturing leather; adhesives for use in industry | SECTION 71 - CANCELLED | — |
| 003 | Bleaching preparations for laundry use; cleaning, polishing, degreasing and abrasive preparations for household purposes | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical, veterinary and sanitary products, namely, pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of stem cell mobilization; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for wounds; pharmaceutical preparations for use in urology; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of viral and infectious diseases and for the treatment of cancer; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals, namely, antihelmitics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; pharmaceuticals, namely, psychotropics; pharmaceuticals, namely, anti-infectives; veterinary preparations, namely, pain relief medication; veterinary preparations for the treatment of intestinal bacteria; veterinary vaccine for horses, veterinary vaccines; sanitary preparations for medical purposes; dietetic foods and beverages adapted for medical use, food for babies; medical plasters, medical dressings; material for dental fillings and dental impressions; disinfectants; preparations for destroying vermin; fungicides, herbicides | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services, namely, research and design services in the field of agrochemicals, pharmaceuticals and bio-chemistry; * analysis of industrial fluids; * design and development of computers and software | SECTION 71 - CANCELLED | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 20, 2026 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Aug 5, 2026 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Aug 5, 2026 | INPC | INVALIDATION PROCESSED | — |
| Jan 2, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 2, 2025 | C71T | CANCELLED SECTION 71 | — |
| Oct 16, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 29, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 7, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 8, 2021 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Feb 2, 2021 | WDRL | OTQR WITHDRAWAL FROM PUBLICATION | — |
| Jan 22, 2021 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Jan 21, 2021 | XXXX | POST REGISTRATION ACTION CORRECTION | — |
| Jun 26, 2020 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Feb 22, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 31, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 31, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 16, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 16, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 31, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 31, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 27, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 19, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 11, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 11, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 11, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 28, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 13, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 7, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 9, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 27, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 27, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 22, 2018 | ALIE | ASSIGNED TO LIE | — |
| Jan 5, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 17, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 28, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 28, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 24, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 23, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 16, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 6, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 2, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 28, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |